Tyrosine Kinase Inhibitor Articles & Analysis: Older
5 articles found
T-DM1, which is bound by trastuzumab and tubulin inhibitor DM1 via a stable, non-lytic, non-reducing thioether linker, was first approved by the FDA in 2013 for use in advanced breast cancer patients with HER2-positive metastases or who have been treated with trastuzumab and taxanes drugs. ...
Lung cancer is a major type of cancer in the world, with the highest morbidity and mortality among all malignant tumors. ALK-positive non-small cell lung cancer (ALK+ NSCLC) is a relatively rare and dangerous subtype, with patients suffering from a high incidence rate of brain metastases. Statistics show that about 55% of ALK-positive advanced NSCLC patients will develop brain metastases during ...
The following takes the virtual screening process of ABL tyrosine kinase inhibitors as an example to briefly describe the construction process of the receptor-based pharmacophore model and its application in virtual screening. STI-571 is a classic tyrosine kinase inhibitor for the treatment of ...
Today, there are only a few therapies approved to treat COVID-19, but while novel therapies can take decades and billions of dollars to develop, are there opportunities to repurpose existing drugs for new therapies? Our latest whitepaper showcases how CAS Knowledge Graphs reveal new connections and insights that identify drugs to potentially repurpose. Drug repurposing is critical for faster ...
A total of 133 patients were enrolled from five treatment centers in France; patients with metastatic disease on non-cytotoxic therapy such as tyrosine kinase inhibitors, immunotherapy or antiangiogenic therapy were eligible. ...